HK1177952A1 - Compositions for vaccinating against hsv-2 hsv-2 - Google Patents

Compositions for vaccinating against hsv-2 hsv-2

Info

Publication number
HK1177952A1
HK1177952A1 HK13105731.8A HK13105731A HK1177952A1 HK 1177952 A1 HK1177952 A1 HK 1177952A1 HK 13105731 A HK13105731 A HK 13105731A HK 1177952 A1 HK1177952 A1 HK 1177952A1
Authority
HK
Hong Kong
Prior art keywords
hsv
compositions
vaccinating against
vaccinating
against hsv
Prior art date
Application number
HK13105731.8A
Other languages
English (en)
Chinese (zh)
Inventor
Michal Margalith
Adrian Vilalta
David M Koelle
Lichun Dong
Original Assignee
Vical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vical Inc filed Critical Vical Inc
Publication of HK1177952A1 publication Critical patent/HK1177952A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
HK13105731.8A 2006-07-20 2013-05-14 Compositions for vaccinating against hsv-2 hsv-2 HK1177952A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80791106P 2006-07-20 2006-07-20
PCT/US2007/074045 WO2008011609A2 (fr) 2006-07-20 2007-07-20 Compositions et méthodes de vaccination contre le hsv-2

Publications (1)

Publication Number Publication Date
HK1177952A1 true HK1177952A1 (en) 2013-08-30

Family

ID=38851640

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13105731.8A HK1177952A1 (en) 2006-07-20 2013-05-14 Compositions for vaccinating against hsv-2 hsv-2

Country Status (7)

Country Link
US (15) US7628993B2 (fr)
EP (1) EP2521786B1 (fr)
JP (3) JP5872755B2 (fr)
AU (1) AU2007275047A1 (fr)
CA (1) CA2658484A1 (fr)
HK (1) HK1177952A1 (fr)
WO (1) WO2008011609A2 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2272859B1 (fr) 1998-08-07 2014-10-22 University of Washington Antigènes immunologiques du virus de l'herpès simplex et méthodes pour leur utilisation
JP5872755B2 (ja) * 2006-07-20 2016-03-01 バイカル インコーポレイテッド 抗ｈｓｖ−２ワクチン接種のための組成物および方法
US9593340B2 (en) * 2007-10-15 2017-03-14 Admedus Vaccines Pty Ltd. Expression system for modulating an immune response
JP2011526888A (ja) * 2008-07-01 2011-10-20 ザ・ジョンズ・ホプキンス・ユニバーシティ 治療薬を標的送達するための経口速溶性薄膜
EP2389362B1 (fr) 2009-01-21 2019-12-11 Oryzon Genomics, S.A. Dérivés de phénylcyclopropylamine et leur utilisation médicale
US9044447B2 (en) 2009-04-03 2015-06-02 University Of Washington Antigenic peptide of HSV-2 and methods for using same
EP3590533A1 (fr) * 2009-05-22 2020-01-08 Genocea Biosciences, Inc. Vaccins contre le virus de l'herpès simplex de type 2 : compositions et procédés pour obtenir une réponse immunitaire
KR101736218B1 (ko) 2009-09-25 2017-05-16 오리존 지노믹스 에스.에이. 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도
EP2486002B1 (fr) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Acétamides d'hétéroaryl- et aryl-cyclopropylamine substitués et leur utilisation
WO2011106105A2 (fr) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibiteurs destinés à une utilisation antivirale
WO2011106573A2 (fr) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibiteurs de la lysine déméthylase utilisés dans le traitement et la prévention de maladies et de troubles associés à hepadnaviridae
ES2607081T3 (es) 2010-04-19 2017-03-29 Oryzon Genomics, S.A. Inhibidores de desmetilasa específica de lisina-1 y su uso
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
HUE037937T2 (hu) 2010-07-29 2021-11-29 Oryzon Genomics Sa Arilciklopropilamin-alapú LSD1-demetiláz inhibitorok és gyógyászati alkalmazásuk
US8557248B2 (en) 2010-08-09 2013-10-15 Cyvax, Inc. Methods and compositions for treating malaria
ES2939732T3 (es) * 2010-08-31 2023-04-26 Glaxosmithkline Biologicals Sa Liposomas pequeños para la administración de ARN que codifica para inmunógeno
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
EP2643014A4 (fr) 2010-11-24 2015-11-11 Genocea Biosciences Inc Vaccins contre le virus de type 2 de l'herpès simplex: compositions et procédés pour la stimulation d'une réponse immunitaire
WO2012072713A2 (fr) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Inhibiteurs de la déméthylase spécifique de la lysine pour des maladies et troubles liés aux flaviviridés
CA2826199A1 (fr) 2011-01-31 2012-08-09 The Trustees Of The University Of Pennsylvania Molecules d'acide nucleique codant de nouveaux antigenes d'herpes, vaccin les comprenant et procedes pour les utiliser
WO2012107498A1 (fr) 2011-02-08 2012-08-16 Oryzon Genomics S.A. Inhibiteurs de lysine diméthylase pour des troubles myéloprolifératifs
EP2502631A1 (fr) * 2011-03-22 2012-09-26 Medizinische Hochschule Hannover Immunosuppresseur et son utilisation
WO2013006401A2 (fr) * 2011-07-01 2013-01-10 Immport Therapeutics, Inc. Méthodes et compositions d'antigènes protéiques pour le diagnostic et le traitement des virus de l'herpes simplex de type 1 et 2
CA2850629C (fr) 2011-10-05 2024-05-21 Genvec, Inc. Vecteurs adenoviraux et procedes d'utilisation associes
US9629906B2 (en) 2011-10-05 2017-04-25 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
EP2764014B1 (fr) 2011-10-05 2022-02-09 GenVec, Inc. Vecteurs adénoviraux et procédés d'utilisation
EP2768805B1 (fr) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. Composés (hétéro)aryl cyclopropyl comme inhibiteurs de lsd1
PE20141692A1 (es) 2011-10-20 2014-11-08 Oryzon Genomics Sa Compuestos de (hetero) aril ciclopropilamina como inhibidores de lsd1
CA2885693C (fr) 2011-11-23 2020-07-28 Genocea Biosciences, Inc. Vaccins a acide nucleique contre le virus d'herpes simplex de type 2 : compositions et procedes pour susciter une reponse immunitaire
WO2013109604A1 (fr) * 2012-01-19 2013-07-25 Alnylam Pharmaceuticals, Inc. Atténuation virale et production de vaccin
CN107540730B (zh) 2012-05-16 2021-07-16 免疫设计公司 用于hsv-2的疫苗
US9676824B2 (en) 2012-05-29 2017-06-13 Genvec, Inc. Herpes simplex virus vaccine
DK2941269T3 (da) 2013-01-07 2021-01-11 Mucosal Vaccine Tech Llc Terapeutiske vacciner til behandling af herpes simplex-virus type 2-infektioner
WO2015048744A2 (fr) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
BR112017017949A2 (pt) 2015-05-15 2018-04-10 Curevac Ag regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
BR112018008090A2 (pt) * 2015-10-22 2018-11-13 Modernatx Inc vacina de vírus do herpes simplex.
WO2018064232A1 (fr) 2016-09-28 2018-04-05 Genocea Biosciences, Inc. Méthodes et compositions pour le traitement d'herpès
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
MA49463A (fr) * 2017-04-26 2021-05-05 Modernatx Inc Vaccin contre le virus de l'herpès simplex
CN118370812A (zh) 2017-08-17 2024-07-23 宾夕法尼亚大学理事会 编码单纯疱疹病毒糖蛋白的修饰mrna疫苗及其用途
EP3938379A4 (fr) 2019-03-15 2023-02-22 ModernaTX, Inc. Vaccins à base d'arn contre le vih
CN110343707B (zh) * 2019-05-30 2021-06-15 中国科学院生物物理研究所 基于乙肝核心抗原的hsv分型用蛋白、试剂盒及方法和应用
CN115227674B (zh) * 2022-08-05 2023-07-04 武汉滨会生物科技股份有限公司 包封的溶瘤病毒遗传物质及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5147055A (en) * 1991-09-04 1992-09-15 Gerry Baby Products Company Diaper container
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
GB9401333D0 (en) * 1994-01-25 1994-03-23 Medical Res Council Herpes virus pre-(viral dna replication) particles (preps)
US5641665A (en) * 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
US5654174A (en) * 1995-07-07 1997-08-05 Competitive Technologies, Inc. Herpes simplex virus glycoprotein D variants
US5972666A (en) * 1996-07-26 1999-10-26 G. D. Searle & Co. Assembly-deficient herpesvirus vaccine
US20020045594A1 (en) * 1997-02-14 2002-04-18 Merck & Co., Inc. Polynucleotide vaccine formulations
EP2272859B1 (fr) * 1998-08-07 2014-10-22 University of Washington Antigènes immunologiques du virus de l'herpès simplex et méthodes pour leur utilisation
ATE272410T1 (de) * 1999-03-26 2004-08-15 Vical Inc Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
WO2000061184A2 (fr) * 1999-04-08 2000-10-19 Glenn Gregory M Formulation seche pour immunisation transcutanee
EP1222281B1 (fr) * 1999-09-30 2006-11-15 University of Washington Antigenes du virus herpes simplex immunologiquement importants
NZ538837A (en) * 1999-11-03 2007-02-23 Powderject Vaccines Inc DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
US20030165819A1 (en) * 2000-06-29 2003-09-04 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6821519B2 (en) * 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
DE10035555A1 (de) * 2000-07-21 2002-01-31 Mann & Hummel Filter Auswechselbare Filterpatrone mit Stützkörper bzw. Flüssigkeitsfilter mit eben dieser Filterpatrone
US6867000B2 (en) * 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
NZ530635A (en) * 2001-06-15 2007-03-30 Nordic Vaccine Technology As Therapeutical vaccination comprising an immunogen and a targeting vehicle comprising a carrier and a antigen silmilar to the first
WO2003011893A2 (fr) * 2001-07-31 2003-02-13 University Of Washington Antigenes du virus de l'herpes simplex (hsv) importants d'un point de vue immunologiques et procedes d'utilisation correspondants
JPWO2003014338A1 (ja) * 2001-08-02 2004-11-25 アンジェスＭｇ株式会社 不活性化ウイルスエンベロープの製造方法
JP2004099584A (ja) * 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
AU2003238892A1 (en) 2002-06-07 2003-12-22 Rmf Dictagene S.A. Secretory signal sequences and uses thereof
CA2492598C (fr) 2002-07-18 2013-12-17 University Of Washington Purification rapide et efficace de t-lymphocytes specifiques au hsv et antigenes a hsv identifies par ce procede
EP1394258A1 (fr) * 2002-08-30 2004-03-03 Geneart GmbH Herpesvirus non humain utilisé comme vecteur
US20050130132A1 (en) * 2002-09-06 2005-06-16 Day Craig H. Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US8080642B2 (en) * 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
US20070274997A1 (en) * 2003-07-25 2007-11-29 Anthony Simmons Compositions and Methods for Herpes Simplex Prophylaxis and Treatment
WO2005012545A2 (fr) * 2003-07-25 2005-02-10 The Regents Of The University Of California Fonction d'un gene de cytomegalovirus et methodes servant a developper des antiviraux, des vaccins anti-cmv et des vecteurs a base de cmv
SG146662A1 (en) 2003-10-10 2008-10-30 Powderject Vaccines Inc Method
JP5331340B2 (ja) * 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
US7288514B2 (en) * 2005-04-14 2007-10-30 The Clorox Company Polymer-fluorosurfactant associative complexes
JP5872755B2 (ja) * 2006-07-20 2016-03-01 バイカル インコーポレイテッド 抗ｈｓｖ−２ワクチン接種のための組成物および方法
JP2008131867A (ja) * 2006-11-27 2008-06-12 Univ Of Tokyo ウイルス粒子の３つのコンポーネントを異なる蛍光タンパク質で標識した組換えウイルス
WO2009005917A2 (fr) 2007-05-29 2009-01-08 Vical Incorporated Procédés de traitement de la maladie infectieuse de la rougeole chez les mammifères

Also Published As

Publication number Publication date
US8834894B2 (en) 2014-09-16
EP2521786A2 (fr) 2012-11-14
AU2007275047A8 (en) 2009-03-12
JP2013138680A (ja) 2013-07-18
US20130202640A1 (en) 2013-08-08
US20140370055A1 (en) 2014-12-18
US20120328656A1 (en) 2012-12-27
US20100158949A1 (en) 2010-06-24
US8263087B2 (en) 2012-09-11
US8840903B2 (en) 2014-09-23
US9205146B2 (en) 2015-12-08
US20120328658A1 (en) 2012-12-27
CA2658484A1 (fr) 2008-01-24
US8852611B2 (en) 2014-10-07
JP5872755B2 (ja) 2016-03-01
US20100040651A1 (en) 2010-02-18
AU2007275047A1 (en) 2008-01-24
US20150030631A1 (en) 2015-01-29
US20100160419A1 (en) 2010-06-24
US7935352B2 (en) 2011-05-03
JP2016052322A (ja) 2016-04-14
US8840904B2 (en) 2014-09-23
EP2521786B1 (fr) 2015-06-24
WO2008011609A2 (fr) 2008-01-24
US8828408B2 (en) 2014-09-09
US8293248B2 (en) 2012-10-23
US9161973B2 (en) 2015-10-20
US20080102087A1 (en) 2008-05-01
US8852610B2 (en) 2014-10-07
US20120328657A1 (en) 2012-12-27
US20130273107A1 (en) 2013-10-17
JP2009544289A (ja) 2009-12-17
WO2008011609A3 (fr) 2008-07-24
US20150010597A1 (en) 2015-01-08
US20130273108A1 (en) 2013-10-17
US7879339B2 (en) 2011-02-01
US20150010596A1 (en) 2015-01-08
US20100160418A1 (en) 2010-06-24
US7628993B2 (en) 2009-12-08

Similar Documents

Publication Publication Date Title
HK1177952A1 (en) Compositions for vaccinating against hsv-2 hsv-2
GB0602424D0 (en) Compounds
GB0602046D0 (en) Compounds
GB0605786D0 (en) Compounds
GB0606876D0 (en) Compounds
EP1984379A4 (fr) Composes anti-arenaviridae
GB0605785D0 (en) Compounds
GB0605784D0 (en) Compounds
EP2082022A4 (fr) Composés
EP2059496A4 (fr) Composés acétyléniques
EP2004174A4 (fr) Composés de naphtalènedione
GB0602042D0 (en) Compounds
EP1973905A4 (fr) Composes
AP2009004767A0 (en) Cubstituted azolin-2-yl-amino compounds
EP2016069A4 (fr) Composé de bis-pyridine
GB0612425D0 (en) Compounds
GB0602560D0 (en) Compounds
GB0602412D0 (en) Compounds
GB0600427D0 (en) Compounds
HU0600193V0 (en) Latch-cover for water-network
GB0602856D0 (en) Compounds
GB0605414D0 (en) Compounds
GB0603132D0 (en) Compounds
GB0603129D0 (en) Compounds
GB0603551D0 (en) Compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190723